Cargando…
Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
Background: Chemotherapy for non-small-cell lung cancer (NSCLC) still leads to unsatisfactory clinical prognosis because of poor active targeting and tumor metastasis. Purpose: The objective of this study was to construct a kind of PFV peptide modified targeted daunorubicin and dioscin codelivery li...
Autores principales: | Wang, Yuanyuan, Fu, Min, Liu, Jingjing, Yang, Yining, Yu, Yibin, Li, Jinyu, Pan, Weisan, Fan, Lei, Li, Guiru, Li, Xuetao, Wang, Xiaobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551515/ https://www.ncbi.nlm.nih.gov/pubmed/31239668 http://dx.doi.org/10.2147/IJN.S194304 |
Ejemplares similares
-
Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017) -
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018) -
Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin
por: Han, Yiqun, et al.
Publicado: (2014) -
Single-Cell Characterization of the Frizzled 5 (Fz5) Mutant Mouse and Human Persistent Fetal Vasculature (PFV)
por: Chen, Yuanyuan, et al.
Publicado: (2023)